AUTHORS
Giulia Carvalhal, MD, Katherin Zambrano-Vera, MD2, Angela Theresa Theresa Zuffo Yabrude, MD3, Cilomar Martins, MD4, Ishan Tatake, MD5, Shruti Chaturvedi Jr, MBBS, MS6, Rushad Patell, MD7
AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Berkshire Medical Center, Pittsfield, Massachusetts, United States
3 Universidade Regional de Blumenau, Blumenau, Santa Catarina, Brazil
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
6 Johns Hopkins University, Baltimore, Maryland, United States
7 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
ABSTRACT
Background: Cold agglutinin disease (CAD) is a complement-mediated autoimmune hemolytic anemia associated with increased thromboembolic risk, with rates as high a 14.2 events per 100 person-years (PMID: 32548562). Sutimlimab rapidly inhibits classical complement-mediated hemolysis, but individual studies are small and provide limited estimates of thrombotic and other clinically relevant outcomes. This study aims at assessing rates of clinical outcomes including thrombosis in adults with CAD treated with sutimlimab.
Methods: This systematic review was conducted according to PRISMA guidelines. PubMed, Embase and Cochrane Library were searched from inception July 2026 for randomized, single-arm, open-label extension, and observational studies. Extension reports were used only in a separate thrombosis analysis to evaluate long-term endpoints, replacing overlapping pivotal reports. Outcomes were change in hemoglobin from baseline, transfusion independence, infections, breakthrough hemolysis, and TE.
We pooled binary outcomes and estimated TE incidence rate/100 patient-years using random-effects generalized linear mixed models. Continuous outcomes were pooled using the generic inverse-variance method. Breakthrough hemolysis was summarized descriptively. Medians- interquartile ranges were converted to means-standard deviations, and change variance assumed a baseline-to-follow-up correlation coefficient of 0.50. Statistical heterogeneity was assessed using the I² statistic.
Results: The database search identified 305 records. Four studies comprising 113 CAD patients met inclusion. These consisted of one randomized controlled trial, two prospective single-arm interventional studies, and one retrospective multicenter cohort study. Follow-up ranged from 7 weeks to a median of 144 weeks in extension reports. Two observational-cohort participants had prior trial enrollment, deemed unlikely to affect pooled estimates.
Across studies, 64% of patients were female, age ranged 65.3-73.5 years, with baseline hemoglobin from 7.8 to 9.2 g/dL, and 57.5% had received at least one red blood cell transfusion within 6 months from enrollment. A prior episode of thrombosis was reported in 21%. Sutimlimab led to an increase in hemoglobin by a pooled mean of 2.69 g/dL (95% CI, 2.37 to 3.01; I²=0%; 4 studies). The pooled proportion of patients who remained transfusion-free was 83.19% (95% CI, 75.14% to 89.01%; I²=0%; 4 studies). Any infection occurred in 38.31% (95% CI, 23.18% to 56.10%; I²=75.9%; 3 studies), although serious infections were less common (12%). In the real-world cohort with the longest follow-up, breakthrough hemolysis occurred in 9 of 57 patients.
Thrombotic events were uncommon during the initial trial periods, 1 TE occurred across 23.5 person-years, with a pooled incidence rate of 4.25/100 person-years (95% CI, 0.60–30.19; I²=0%; 3 studies; 56 patients; 7 to 25 weeks of follow-up). During extension reports, evaluating the longest available follow-up and the observational cohort, 6 TEs occurred across 291.1 estimated person-years, corresponding to a pooled incidence rate of 2.06/100 person-years (95% CI, 0.93–4.59; I²=0%; 4 studies; 131 patients; 80 to 144 weeks of follow-up). Events were predominantly venous, including catheter-associated thrombosis, and isolated arterial events (transient ischemic attack and peripheral arterial thrombosis) were also reported. All reported events were nonfatal and considered unrelated to sutimlimab by the study investigators. Sensitivity analysis, restricted to clinical trials, showed 5 TEs occurred across 167.6 person-years, yielding a pooled incidence rate of 2.98/100 person-years (95% CI, 1.24–7.17; I²=0%; 3 studies; 74 patients; 80 to 144 weeks of follow-up). In a recent post hoc analysis of patients enrolled in the phase 3 studies, the TE rate decreased from 7.5 to 4.4/100 patient-years after sutimlimab initiation.
Conclusion: In this systematic review and meta-analysis, sutimlimab was associated with a rapid and clinically meaningful increase in hemoglobin and high rates of transfusion independence in adults with CAD. TEs were infrequent during both primary and longer-term follow-up, although estimates were imprecise because of the small numbers. These findings support the hematologic efficacy of sutimlimab, while underscoring the need for larger real-world studies and continued longitudinal surveillance to better define its effects on thrombotic risk, infections, and breakthrough hemolysis.
DISCLOSURES
Giulia Carvalhal, MD: No relevant conflicts of interest to declare.